Scientific discoveries typically begin at the bench, with basic research through the study of diseases at a molecular or cellular level, then progress to the clinical level, or the patient’s bedside. Scientists are increasingly aware that this bench-to-bedside approach to translational research is actually a two-way street. Basic scientists provide clinicians with new tools for use in patients and for assessment of their impact, while clinical researchers make novel observations about the nature and progression of disease and gather biospecimens that are necessary to fuel the next generation of basic investigations.

The National Cancer Institute (NCI) is committed to the discovery and development of new and effective therapies for cancer. As a result, about half of the drugs used to treat cancer today are due to NCI’s efforts. The Developmental Therapeutics Program (DTP), within the Division of Cancer Treatment and Diagnosis (DCTD) is the drug development arm of NCI. Working with academic scientists, clinicians and commercial companies, DTP has contributed to the rapid development of drugs and therapies to improve cancer treatment.